BioSpace News Archive

Algernon Pharmaceuticals Inc. is pleased to announce that Harry Bloomfield, QC. has been appointed as a new member of the Board of Directors and has been elected Chairman of the Board.

ASLAN Pharmaceuticals today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the H.C. Wainwright 23rd Annual Global Investment Conference on 13 September, 2021.

AbbVie (NYSE: ABBV) and Genmab A/S (Nasdaq: GMAB) today announced The Lancet published the results of the dose escalation part of the Phase 1/2 EPCORE™ NHL-1 first-in-human (FIH) dose escalation and cohort expansion clinical trial evaluating safety and preliminary efficacy of the investigational therapy epcoritamab (DuoBody®-CD3xCD20) in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma (B-NHL).

iECURE today announced it has closed a $50 million Series A financing led by Versant Ventures and OrbiMed Advisors.

Precision BioSciences today provided strategic business updates on its in vivo gene editing pipeline during the Company’s first gene editing R&D event.

Positive high-level results from the MANDALA and DENALI Phase III trials of PT027.

NeoGenomics, Inc. today announced that its liquid biopsy focused subsidiary Inivata Limited alongside collaborators, will present new data on its RaDaR assay for the detection of molecular residual disease (MRD) and recurrence and on its InVisionFirst-Lung liquid biopsy test at the European Society on September 16-21, 2021.

Telix Pharmaceuticals Limited announces that it has entered into an exclusive licence agreement for a novel positron emission tomography radiotracer that originates from the Université catholique de Louvain.

According to the report, the global oral thin films market was valued at US$ 2.6 Bn in 2019. It is projected to expand at a CAGR of ~9% from 2020 to 2030.

In the course of the most recent few decades, the medicinal services market has seen the passage of a few successful treatment choices for malignant growth; these incorporate an assortment of focused treatments, immunotherapies, and disease antibodies also.